Since BIRC5 is reported to be an immune-associated gene that promotes tumor progression, many studies related to survivin in NSCLC focus on the sensitization to chemotherapy, radiotherapy, and targeted therapy, with little success achieved due the heterogeneity of this disease [19,20]. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.